Register here .

Attendees will hear from the NCI’s Dr. Mitchell Ho  about a potential therapeutic treatment for COVID-19, “Single Domain Antibodies Targeting SARS-CoV2 for Treating Covid-19.”  There are few therapeutics available for COVID-19 patients that directly target the SARS-CoV-2 novel coronavirus. COVID-19 is caused by SARS-CoV-2, which infects hosts via its spike (S) protein. The S protein contains a receptor binding domain (RBD) that binds to an angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. Dr. Ho’s lab isolated three lead nanobodies, 7A3, 1B5, and 2F7, which were found to be highly effective at blocking RBD-ACE2 binding interactions. This nanobody panel has the potential to block the binding of the S-protein to the ACE2 receptor, thereby preventing SARS-CoV-2 virus from binding to and entering a host cells to cause COVID-19 infection.

Why attend?

• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn the advantages of partnering with the NCI

Who should attend?

• Business development professionals
• Drug development professionals
• Biotech/pharma/academic researchers
• Investors and entrepreneurs

About the featured technology

This technology is pre-clinical with identified lead compounds. It is patent pending and available for licensing or co-development.